111 related articles for article (PubMed ID: 33635005)
21. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
22. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
23. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
24. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
26. circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression.
Chen B; Wei W; Huang X; Xie X; Kong Y; Dai D; Yang L; Wang J; Tang H; Xie X
Theranostics; 2018; 8(14):4003-4015. PubMed ID: 30083277
[TBL] [Abstract][Full Text] [Related]
27. Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling.
Singh S; Kumar S; Srivastava RK; Nandi A; Thacker G; Murali H; Kim S; Baldeon M; Tobias J; Blanco MA; Saffie R; Zaidi MR; Sinha S; Busino L; Fuchs SY; Chakrabarti R
Nat Cell Biol; 2020 May; 22(5):591-602. PubMed ID: 32284542
[TBL] [Abstract][Full Text] [Related]
28. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
29. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
[TBL] [Abstract][Full Text] [Related]
30. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.
Menbari MN; Rahimi K; Ahmadi A; Mohammadi-Yeganeh S; Elyasi A; Darvishi N; Hosseini V; Abdi M
J Cell Physiol; 2020 Mar; 235(3):2631-2642. PubMed ID: 31508813
[TBL] [Abstract][Full Text] [Related]
31. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
Son D; Kim Y; Lim S; Kang HG; Kim DH; Park JW; Cheong W; Kong HK; Han W; Park WY; Chun KH; Park JH
Cancer Lett; 2019 Jul; 454():224-233. PubMed ID: 31004703
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
33. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
[TBL] [Abstract][Full Text] [Related]
34. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
[TBL] [Abstract][Full Text] [Related]
35. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
36. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
37. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
[TBL] [Abstract][Full Text] [Related]
39. miR-506-loaded gelatin nanospheres target PENK and inactivate the ERK/Fos signaling pathway to suppress triple-negative breast cancer aggressiveness.
Liu XL; Liu WJ; Chen Q; Liu J; Yang CQ; Zhang G; Zhang SL; Guo WH; Li JB; Zhao G; Yin DC; Zhang CY
Mol Carcinog; 2021 Aug; 60(8):538-555. PubMed ID: 34062009
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
